Summary & Overview
HCPCS J7356: Injection, foscarbidopa 0.25 mg/foslevodopa 5 mg
HCPCS Level II code J7356 designates the injectable combination product foscarbidopa 0.25 mg/foslevodopa 5 mg. This code captures administration of a specialized levodopa prodrug formulation used in treating Parkinsonian movement disorders and related indications requiring parenteral delivery. Nationally, accurate coding of this medication is important for billing consistency, utilization tracking, and ensuring appropriate coverage determinations for high-cost specialty injectables.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the agent, typical sites of service where administration occurs, and operational considerations for billing under HCPCS Level II. The publication also summarizes available benchmarks and payer coverage patterns where provided, highlights relevant policy updates affecting reimbursement and prior authorization practices, and outlines associated billing elements such as common modifiers and service-line considerations.
The content is intended for revenue cycle professionals, clinicians involved in infusion therapy, and policy analysts seeking a national-level briefing on coding and payer interactions for this injectable therapy.
Billing Code Overview
HCPCS Level II code J7356 describes an injection of foscarbidopa 0.25 mg/foslevodopa 5 mg. This drug-based billing code represents administration of a combination agent used in the management of Parkinsonian symptoms and related movement disorders where levodopa/carbidopa therapy is indicated.
Service Type: Drug administration (injectable therapy)
Typical Site of Service: Infusion center, outpatient clinic, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced Parkinson disease experiencing motor fluctuations and unpredictable "off" periods despite oral carbidopa/levodopa therapy. The patient presents to an outpatient infusion center or hospital specialty pharmacy clinic for initiation or dose adjustment of an intravenous bolus formulation of foscarbidopa/foslevodopa (injectable conversion to active carbidopa/levodopa). The clinical workflow includes: pre-procedure medication reconciliation and informed consent; baseline neurologic assessment (UPDRS motor exam or equivalent); verification of weight and current oral dose; preparation of the injectable per pharmacy compounding protocols; administration of the J7356 injection by an RN under neurology or movement disorders specialist supervision; monitoring for acute adverse effects (orthostatic hypotension, dyskinesia, nausea) for 30–60 minutes post-injection; documentation of dose given, lot number, and patient response; and scheduling follow-up for home infusion planning or transition back to optimized oral therapy. Typical sites of service are outpatient infusion centers, ambulatory surgery centers when combined with other procedures, hospital inpatient units for acute management, and specialty clinic infusion rooms. Typical patient scenario modifiers may include medical necessity or unusual circumstances such as procedural complexity or patient-related factors affecting administration and billing documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |